- Report
- October 2024
- 187 Pages
Global
From €3234EUR$3,545USD£2,764GBP
€3593EUR$3,939USD£3,071GBP
- Report
- April 2025
- 286 Pages
Global
From €5337EUR$5,850USD£4,561GBP
- Report
- December 2024
- 172 Pages
Global
From €2281EUR$2,500USD£1,949GBP
- Report
- October 2023
- 190 Pages
Global
From €4105EUR$4,500USD£3,509GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
Droxidopa is a synthetic amino acid used to treat symptomatic neurogenic orthostatic hypotension (NOH) in adults. It is a cardiovascular drug that works by increasing the levels of norepinephrine, a neurotransmitter that helps regulate blood pressure. It is available in capsule form and is taken orally.
Droxidopa is used to treat the symptoms of NOH, such as dizziness, lightheadedness, and fatigue. It is also used to improve quality of life in patients with NOH. It is not recommended for use in patients with severe hypertension or heart failure.
The Droxidopa market is composed of pharmaceutical companies that manufacture and distribute the drug. These companies are involved in research and development, manufacturing, marketing, and distribution of the drug. They also provide support services such as patient education and counseling.
Some companies in the Droxidopa market include Lundbeck, Jazz Pharmaceuticals, and Avanir Pharmaceuticals. Show Less Read more